Biomarkers can be proteins, cellular components, physiologic, or imaging findings that relate specifically to an injury or disease that is occurring. Biomarkers are by definition objective, quantifiable characteristics of biological processes.

Banyan Biomarkers is developing Banyan Ubiquitin C-terminal Hydrolase-L1TM (UCH-L1) and Banyan Glial Fibrillary Acidic ProteinTM (GFAP) which are two novel protein biomarkers that are brain specific and detectable in the blood shortly after TBI. UCH-L1 is primarily found in neurons and is involved in cellular protein regulation. GFAP is a member of the intermediate filament family of cytoskeletal proteins which form polymeric networks that provide structural support to glia to support and nourish cells in the brain. Banyan believes that accurate diagnosis of TBI in acute care environments could significantly simplify decisions about patient management including whether to admit or discharge from the hospital.